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cerns about safety and impact on patient outcomes. 
Attitudes about the proliferation of messages they per-
ceive as “false-positives” could explain the inconsistency
among pharmacist responses to drug interaction messages
(DIMs). Our objective is to report a pilot study examin-
ing pharmacist utilization and perceptions of DIMs.
METHODS: A semi-structured telephone interview 
protocol was developed using Likert scales assessing
pharmacists’ utilization and attitudes regarding DIMs.
Utilization measures included perception of false positive
DIMs and desensitization to DIMs. Attitude assessments
included conﬁdence, usefulness, and satisfaction with 
the drug interaction programs, and inﬂuence of liability
concerns. A convenience sample of 44 West Virginia 
pharmacists responded during March 2002. ANOVA was
used to analyze relationships among variables in this
descriptive study. RESULTS: Among respondents, 36.4%
perceived that 21–30% of DIMs were insigniﬁcant;
13.5% perceived that >50% of DIMs were insigniﬁcant.
Using a 5-point scale (1 = not at all, 5 = very much), phar-
macists reported desensitization to DIMs (median = 4.0).
Pharmacists perceiving DIMS as more insigniﬁcant also
reported greater desensitization to DIMs (F = 3.04, p <
.05). Pharmacists found the programs useful (median =
4.0), were somewhat conﬁdent (median = 3.5) or satisﬁed
with the programs (median = 3.0). Those who found the
program more useful (F = 6.38, p < .05), or were more
conﬁdent (F = 3.09, p < .05) or satisﬁed with the program
(F = 6.95, p < .05), were signiﬁcantly less desensitized to
DIMs. Also, the more desensitized to DIMs, the more 
the pharmacist was inﬂuenced by liability concerns in
deciding to report a DIM to the patient and/or physician
(F = 4.54, p < .01). CONCLUSIONS: These pilot results
suggest further research is warranted. Pharmacist utiliza-
tion of drug interaction programs is inconsistent; this may
be inﬂuenced by attitudes towards DIMs. Information
regarding attitudinal barriers can provide content for
pharmacist training or for vendor development of drug
interaction programs.
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OBJECTIVES: Utah Medicaid began a process to limit
patients to 7 paid non-exempt prescriptions per month
(maximum 30 day supply) in early 2002. Exempt 
prescriptions included prescriptions for antibiotics and
many chronic drugs, and more than one prescription for
the same NDC in the same month. One-third of pre-
scriptions are exempt. Prior to mandating the 7 prescrip-
tion limit Utah Medicaid contracted to develop a process
to improve drug use and reduce costs. The project objec-
tive is to describe and evaluate that process. METHODS:
Available data include eligibility ﬁles, pharmacy claims,
and medical claims, including ICD9 coding. Reviews
began in May 2002 and focus on the highest utilizers.
Two hundred patients are reviewed each month; 50
nursing home patients and 150 non-nursing home
patients. There were 249,447 Medicaid eligibles and
147,186 utilizers in FY2002. If drug related issues are
identiﬁed, letters are sent to prescribers with recommen-
dations along with a list of all prescription claims 
(including cost). RESULTS: Patients with >7 non-exempt
prescriptions have been reduced from 5593 in May 2002
to 2326 in September 2002. The ﬁrst review cohort (May
reviews) showed a reduction from 16.4 to 10.7 in mean
non-exempt prescriptions. Drug costs for the May cohort
in October were 46% lower than in May. The June and
July cohorts were reduced by 32% and 25% respectively;
June vs October, and July vs October while drug costs 
for non-reviewed patients increased at a 16% annual 
rate. Actual drug costs for the May cohort from May to
October were $1,042,643. This compares with an
expected cost of $1,592,564 (May costs increased by 
an annual 16%). Annualized cost savings for the May, 
June, and July cohorts are approximately $2.3M.
Program costs are approximately $300,000 per year.
CONCLUSION: Focused reviews of Medicaid high uti-
lizers, and communication with prescribers, can reduce
drug costs.
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OBJECTIVES: The objective of this study was to assess
whether prescribing incentive schemes offered to general
practitioners in England give appropriate incentives 
for cost-effective prescribing. METHODS: Prescribing
advisers from primary care trusts (PCTs) in England were
surveyed and asked to provide a copy of their prescrib-
ing incentive scheme, if available. The schemes were then
analysed in order to assess the types of incentives offered,
the targets (budgetary and non-budgetary) set and the
therapeutic areas covered. RESULTS: Responses were
obtained from 161 (50.4%) of the 319 PCTs existing 
in England in 2002. Of those responding, 109 supplied
copies of their prescribing incentive scheme, others stated
that their scheme was not ﬁnalized (N = 34), or offered
other reasons why it could not be supplied, such as 
conﬁdentiality concerns, or that no scheme was under
development. Of the schemes analysed, 26% offered the
maximum annual incentive of £45,000 per practice.
However, many offered incentives much lower than this
